Press Releases

The global viral and non-viral vector manufacturing market is projected to grow at a 18.45% CAGR during 2025-2030. In order to efficiently transfer therapeutic genes into target cells, viral or non-viral vector methods are used. Adenovirus, lentivirus, retrovirus, and adeno-associated viral (AAV) vectors are examples of viral vectors used in gene therapy. Non-viral vectors rely on plasmid DNA delivery in most cases. The increased prominence of target diseases and disorders, rising use of nucleic acid therapeutics in non-viral vectors, increased funding for gene therapy development, the efficacy of viral vectors in gene therapy delivery, and continuous R&D in gene and cell therapies will drive the growth of the viral and non-viral vector manufacturing market. Government initiatives such as direct funding for viral vector production are raising awareness, while the regulatory environment is being streamlined through changes such as expedited approval processes that are propelling the market's growth. However, the high cost of gene therapies and challenges in viral vector manufacturing capacity may have a negative impact on market growth.

In October 2021, Boehringer Ingelheim, IP Group, the UK Cystic Fibrosis Gene Therapy Consortium, and Oxford Biomedica (OXB) stated that Boehringer Ingelheim has exercised its options on intellectual property and know-how from the partners in order to advance and accelerate the development of a potential new treatment option for CF patients. In the partnership, IP Group grants exclusive global rights to develop, manufacture, register, and commercialize this lentiviral vector-based gene therapy for the treatment of cystic fibrosis on behalf of the three GTC host universities. The GTC also contributes expertise in pre-clinical research and clinical gene therapy development. OXB is complementing Boehringer Ingelheim's expertise in the development of novel breakthrough therapies for respiratory diseases with its leading expertise in manufacturing lentiviral vector-based therapies.

Browse 73 market data Tables and 47 Figures spread through 200 Pages and in-depth TOC on " Viral and Non-Viral vector Manufacturing Market by Vector Type (Viral Vector (Adenoviral Vector, Retroviral Vector, Adeno-Associated Viral Vector, Lentiviral Vector, Vaccinia Viral Vector, and Other Viral Vector) and Non-Viral Vector (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, and Other Non-Viral Vector)), by Disease (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, and Other Diseases), by Application (Gene Therapy, Vaccinology, Cell Therapy, and Others), and Region - Global Forecast to 2030"

By vector type, plasmid DNA is non-viral vector contribute to the largest share in the market.

The global viral and non-viral vector manufacturing market is divided into viral vector and non-viral vector segments based on vector type. Adenoviral Vector, Retroviral Vector, Adeno-Associated Viral Vector, Lentiviral Vector, Vaccinia Viral Vector, and Other Viral Vector are the different types of viral vector. Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, and Other Non-Viral Vector are the several types of the non-viral vector. The plasmid DNA segment dominated the global viral vector & non-viral vector manufacturing market and the trend is expected to continue over the projected period owing to the rising adoption of plasmid DNA as raw material in the manufacture of viral vectors, thereby propelling the growth of the segment.

Global Viral and Non-Viral Vector Manufacturing Market Segmentation and Key Players

Discover More About This Report, Download A Free Sample Copy of Global Viral and Non-Viral Vector Manufacturing Market

“Asia-Pacific is anticipated to have fastest growth in the Viral and Non-Viral vector Manufacturing market during 2025-2030.”

Asia-Pacific is anticipated to grow at a faster pace in the viral and non-viral vector manufacturing market owing to continuous clinical trials on gene therapy in countries like Japan and China, rising health awareness, technological development in the pharmaceutical industry, and high prevalence of cancer diseases in the region will propel the growth of the market.

Some of the major players in the global viral and non-viral vector manufacturing market include Boehringer Ingelheim International GmbH, Catalent, Inc, GenScript ProBio, Lonza, Merck KGaA, Oxford Biomedica, Sartorius AG, Takara Bio Inc., Thermo Fisher Scientific Inc., and Evonik Industries AG.

Global Viral and Non-Viral Vector Manufacturing Market Coverage

Vector Type Insight and Forecast 2025-2030

• Viral Vector
  • Adenoviral Vector
  • Retroviral Vector
  • Adeno-Associated Viral Vector
  • Lentiviral Vector
  • Vaccinia Viral Vector
  • Other Viral Vector
• Non-Viral Vector
  • Plasmid DNA
  • Lipid-Based Non-Viral Vector
  • Polymer-Based Non-Viral Vector
  • Other Non-Viral Vector

Disease Insight and Forecast 2025-2030

• Cancer
• Genetic Disease
• Infectious Disease
• Cardiovascular Disease
• Other Diseases

Application Insight and Forecast 2025-2030

• Gene Therapy
• Vaccinology
• Cell Therapy
• Others

Geographical Segmentation

Viral and Non-Viral Vector Manufacturing Market by Region

North America

• By Vector Type
• By Disease
• By Application
• By Country – U.S., Canada, and Mexico

Europe

• By Vector Type
• By Disease
• By Application
• By Country – Germany, U.K., France, Italy, Spain, Russia, and Rest of Europe

Asia-Pacific (APAC)

• By Vector Type
• By Disease
• By Application
• By Country – China, Japan, India, South Korea, and Rest of Asia-Pacific

Rest of the World (RoW)

• By Vector Type
• By Disease
• By Application
• By Country – Brazil, Saudi Arabia, South Africa, U.A.E., and Other Countries